VARUBI IV is the first NK-1 RA in a ready-to-use vial1-3
- Injectable emulsion does not require reconstitution
- Single-dose vial
- Free of polysorbate 80
Please see complete dosing and administration information in the Prescribing Information.
IV, intravenous; NK-1, neurokinin 1; RA, receptor antagonist.
Because delayed CINV shouldn't define her.
Indication: VARUBI® (rolapitant), in combination with other antiemetic agents, is indicated in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Contraindication: VARUBI is contraindicated in patients receiving thioridazine, a CYP2D6 substrate. A significant increase in plasma concentrations of thioridazine may result in QT prolongation and Torsades de Pointes.
CINV, chemotherapy-induced nausea and vomiting.
Despite antiemetic treatment,More than half are still suffering4
The majority of patients undergoing highly or moderately emetogenic chemotherapy (HEC or MEC) experience delayed chemotherapy-induced nausea and vomiting (CINV)—even when prescribed a 5-hydroxytryptamine-3 (serotonin) receptor antagonist (5-HT3 RA) and a corticosteroid.4
VARUBI® (rolapitant) as part of an antiemetic regimen:Proven protection with one dose1
Warnings and precautions
Interaction with CYP2D6 substrates with a narrow therapeutic index
- The inhibitory effect of VARUBI on CYP2D6 lasts for at least 7 days and may last longer after administration of a single dose of VARUBI
- Avoid use of VARUBI in patients who are receiving pimozide, a CYP2D6 substrate. An increase in plasma concentrations of pimozide may result in QT prolongation
- Monitor for adverse reactions if concomitant use of VARUBI and other CYP2D6 substrates with a narrow therapeutic index cannot be avoided